Related references
Note: Only part of the references are listed.Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment
Christine Hsu et al.
ONCOLOGIST (2020)
A review of the imaging manifestations of immune check point inhibitor toxicities
Richard Thomas et al.
CLINICAL IMAGING (2020)
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune-related pancreatitis associated with checkpoint blockade in melanoma
Johannes Kohlmann et al.
MELANOMA RESEARCH (2019)
Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis
John George et al.
PANCREATOLOGY (2019)
Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication
Jean-Marie Michot et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Initial Medical Treatment of Acute Pancreatitis: American Gastroenterological Association Institute Technical Review
Santhi Swaroop Vege et al.
GASTROENTEROLOGY (2018)
American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis
Seth D. Crockett et al.
GASTROENTEROLOGY (2018)
Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy
Thiru Prasanna et al.
IMMUNOTHERAPY (2018)
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis
Qiang Su et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab plus Ipilimumab
Claire F. Friedman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab plus Ipilimumab
Claire F. Friedman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Lipase or amylase for the diagnosis of acute pancreatitis?
Ola Z. Ismail et al.
CLINICAL BIOCHEMISTRY (2017)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
Sree Harsha Tirumani et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus
Peter A. Banks et al.
GUT (2013)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Share Paper
